 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Name: | Letrozol , Femara | CAS: | 112809-51-5 |
|---|---|---|---|
| Apperance: | White Powder | Purity: | 99% |
| Packing: | Discreet Package For Delivery Guarantee | FM: | C17h11n5 |
| Type: | Pharmaceutical Intermediates | Usage: | Pharmaceutical Raw Material |
| High Light: | Cas 112809-51-5,Anti Estrogen Pharma Intermediates,Bodybuilding Pharma Intermediates |
||
Product Description
Specification:
| Product name: | Letrozol/Femara |
| CAS No.: | 112809-51-05 |
| Assay: | 99%min |
| Molecular Formula: | C17H11N5 |
| Molecular weight: | 285.31 |
| Character: | White or pale white crystalline powder |
| MOQ: | 10 grams |
| Standard: | Enterprise Standard |
| Packing | foil bag or tin |
| Delivery | Express courier |
Usage: used in the treatment of breast cancer, letrozol is a new generation of aromatase inhibitors, for the artificial synthesis of benzyl three azole derivatives, letrozol by inhibition of aromatase, which decreases the level of estrogen, thereby eliminating the stimulating effect of estrogen on the growth of tumor.
Specifications:
| Tests | Specifications | Results |
| Appearance | White or off-white crystaline powder | White Crystalline powder |
| Solubility | Soluble in Chloroform; Soluble in ethanol when heated |
Conform |
| ldentification | (1)Maximum absorption in wavelength of 240 nm Minimum absorption in wavelength of 215 nm |
Conform Conform |
| (2)Infrared spectrum should be in accordance the dominant peak of contrast | In accordance with the dominant peak of contrast | |
| Melting points | 182ºC-184ºC | 182ºC |
| Related substances | ≤0.5% | 0.3% |
| Single impurity | ≤0.3% | 0.2% |
| Loss on drying | ≤1.0% | 0.8% |
| [Assay]C17H11N5 (On anhydrous basis) |
≥98.0% | 99.2% |
| Conclusion | Conforms Specifications of Enterprise Standard. | |
Detail:
Femara is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.
Femara is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs, like tamoxifen. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.
Femara is used for the treatment of post-menopause breast cancer.
Femara is a powerful Aromatase Inhibitor that was developed to fight breast cancer. For athletes and bodybuilders, it is a drug used to combat the estrogenic side effects of anabolic steroids water-retention, acne and gynocomastia. It will also raise testosterone levels because of the lowered estrogen in the body.
Contact Person: July
Tel: 25838890
